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Abstract
Background: Influenza infections are often complicated by secondary infections,
which are associated with high morbidity and mortality, suggesting that influenza
profoundly influences the immune response towards a subsequent pathogenic
challenge. However, data on the immunological interplay between influenza and
secondary infections are equivocal, with some studies reporting influenza-induced
augmentation of the immune response, whereas others demonstrate that influenza
suppresses the immune response towards a subsequent challenge. These contrasting
results may be due to the use of various types of live bacteria as secondary
challenges, which impedes clear interpretation of causal relations, and to differences
in timing of the secondary challenge relative to influenza infection. Herein, we
investigated whether influenza infection results in an enhanced or suppressed innate
immune response upon a secondary challenge with bacterial lipopolysaccharide
(LPS) in either the acute or the recovery phase of infection.
Methods: Male C57BL/6J mice were intranasally inoculated with 5 × 103 PFU
influenza virus (pH1N1, strain A/Netherlands/602/2009) or mock treated. After 4
(acute phase) or 10 (recovery phase) days, 5 mg/kg LPS or saline was administered
intravenously, and mice were sacrificed 90 min later. Cytokine levels in plasma and
lung tissue, and lung myeloperoxidase (MPO) content were determined.
Results: LPS administration 4 days after influenza infection resulted in a synergistic
increase in TNF-α, IL-1β, and IL-6 concentrations in lung tissue, but not in plasma.
This effect was also observed 10 days after influenza infection, albeit to a lesser
extent. LPS-induced plasma levels of the anti-inflammatory cytokine IL-10 were
enhanced 4 days after influenza infection, whereas a trend towards increased
pulmonary IL-10 concentrations was found. LPS-induced increases in pulmonary
MPO content tended to be enhanced as well, but only at 4 days post-infection.
Conclusions: An LPS challenge in the acute phase of influenza infection results in an
enhanced pulmonary pro-inflammatory innate immune response. These data
increase our insight on influenza-bacterial interplay. Combing data of the present
study with previous findings, it appears that this enhanced response is not beneficial
in terms of protection against secondary infections, but rather damaging by
increasing immunopathology.
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Background
Patients with influenza infection often suffer from severe secondary bacterial infections,
which are associated with high morbidity and mortality rates [1, 2]. A striking example
of this relationship was provided by bacteriological and histopathological analysis of in-
fected lung tissue obtained from people who died of influenza during the 1918–1919
“Spanish flu” pandemic, in whom bacterial pneumonia was found to be the predomin-
ant cause of death [1]. These data suggest that an influenza infection profoundly influ-
ences the immune response upon a secondary bacterial infection.
Several studies have evaluated immunological interactions between influenza and
bacterial infections, including infections with Gram-negative bacteria [3]. In vitro
studies in which influenza-infected alveolar macrophages were subsequently
stimulated with bacterial lipopolysaccharide (LPS), a bacterial compound that
induces a profound innate immune response, revealed increased levels of
pro-inflammatory cytokines tumor necrosis factor (TNF) α, interleukin (IL)-1β, and
IL-6 [4–8], indicative of a priming effect on these cells by influenza. Data from in
vivo animal studies are ambiguous. Similar to the in vitro data, some report
enhanced responses. For instance, influenza infection in mice was shown to enhance the
inflammatory response and neuropathogenicity resulting from LPS administration
on days 3 and 4 after influenza inoculation [9]. Likewise, murine influenza
infection resulted in increased levels of pro-inflammatory cytokines in both plasma
and lungs, and enhanced pulmonary neutrophil influx upon pneumococcal
infection 7 days later [10]. Similar results were observed in mice 14 days after
influenza infection [11]. However, two otherwise largely comparable studies
demonstrated reduced pulmonary pro-inflammatory cytokine concentrations upon
Streptococcus pneumoniae and Staphylococcus aureus infections in mice infected
with influenza 7 days before, indicative of influenza-induced immunosuppression
[12, 13]. These equivocal results may be due to differences in the severity or
kinetics of the influenza infection or the use of different bacteria as secondary
challenges, thereby targeting various complex multi-receptor signaling pathways.
Also, the use of live bacteria could have contributed to these ambiguous results.
For instance, if influenza would induce immunosuppression and thereby facilitate
outgrowth of bacteria upon a secondary live infectious challenge, the increased
bacterial burden can eventually result in fulminant inflammation, which would
wrongfully suggest influenza-induced augmentation of the immune response.
In the present study, we investigated whether influenza infection results in an en-
hanced or suppressed innate immune response upon a secondary challenge with LPS.
Furthermore, we assessed the kinetics of these influenza-induced effects by performing
the LPS challenges in either the acute or the recovery phase of influenza infection.
Methods
Ethics and animals
All procedures described were in accordance with the requirements of the Dutch
Experiments on Animals Act, the EC Directive 86/609, and approved by the Animal
Ethics Committee of the Radboud University Nijmegen Medical Center (RU-DEC
2013-029). Forty-eight male C57BL/6J mice (Charles River, Sutzfield, Germany) aged
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10–12 weeks and weighing 23–29 g were used. Mice were housed in individually venti-
lated cages, with five mice per cage at the central animal facility of the Radboud
University.
Study design
At day 0, six groups of eight mice (total n = 48) were anesthetized by isoflurane and
intranasally inoculated with a sublethal dose of influenza virus (pH1N1, strain A/
Netherlands/602/2009, 5 × 103 PFU) or mock treated (NaCl 0.9%) in a volume of
50 μL. Following infection, all mice were monitored and weighed daily. The
temperature was recorded with an infrared thermometer on the skin, and physical con-
dition was scored using a scoring and weight sheet (weight, body temperature, ruffled
coat, hunched back, reduced mobility, and moribund). At either day 4 (acute phase) or
day 10 (recovery phase), mice were placed in a temperature-controlled chamber to re-
ceive LPS (E coli, serotype 0111:B4, 5 mg/kg) or NaCl 0.9% by intravenous injection in
the tail vein. Ninety minutes after LPS or NaCl administration, mice were deeply anes-
thetized with isoflurane and exsanguinated through orbital extraction, followed by cer-
vical dislocation after which organs were collected.
Blood and tissue collection
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood was centrifuged at
13000×g for 2 min at room temperature after which plasma was stored at − 80 °C until
analysis. Subsequently, perfusion of the lungs was performed by intracardiac injection
with phosphate-buffered saline (PBS), after which lung lobes were harvested and snap
frozen in liquid nitrogen and stored at − 80 °C until homogenization. Lung tissue was
placed in 1 mL lysis buffer containing PBS, 0.5% triton X-100, and a protease inhibitor
cocktail (complete EDTA-free tablets, Roche, Woerden, the Netherlands, 1 tablet per
50 mL lysis buffer). Subsequently, lung lobes were homogenized at 50 Hz, using a poly-
tron homogenizer, and subjected to two rapid freeze-thaw cycles using liquid nitrogen.
Finally, homogenates were centrifuged (10 min, 14,000×g, 4 °C), and the supernatant
was stored at − 80 °C until cytokine analysis.
Cytokine analysis
Concentrations of TNF-α, IL-1β, IL-6, and IL-10 in plasma and lung homogenates were
measured using a Luminex assay (Milliplex, Millipore, Billerica, MA) according to the
manufacturer’s instructions. The lower detection limit of the assay was 32 pg/mL for all
cytokines. Plasma IL-1β levels were below the detection limit in the majority of animals.
Lung homogenate cytokine concentrations were normalized to total protein content de-
termined by bicinchoninic acid assay (BCA Protein Assay; Thermo Fisher Scientific).
Myeloperoxidase content
Myeloperoxidase (MPO) content was measured in lung homogenates using an enzyme-linked
immunosorbent assay (Hycult biotech, Uden, the Netherlands) according to the
manufacturer’s instructions. Concentrations were normalized to total protein con-
tent as described above.
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Statistical analysis
All data were normally distributed according to the Shapiro-Wilk test. The Grubbs
test (extreme studentized deviate method) was used to exclude significant outliers
from analysis (maximum of one exclusion per dataset). To determine the number
of animals required per group, we performed a power calculation based on a min-
imal detectable difference of 50% in LPS-induced plasma TNF-α levels between
influenza-infected and non-influenza-infected mice. Mean ± SD (533 ± 163 pg/mL)
TNF-α plasma levels were obtained from previous work from our group, in which
male C57BL/6J mice were also injected intravenously with 5 mg/kg LPS and sacri-
ficed 90 min later [14]. Using a two-sided α of 0.05 and a power of 80% (β of 0.2)
in an unpaired t test design, six animals per group were required. To account for
potential loss of animals due to influenza infection, eight animals per group were
used. The effect size was based on previous work [9], in which influenza infection
modulated the plasma cytokine response to LPS administration by at least 50%.
Comparisons were analyzed using unpaired Student’s t tests and repeated measures
one-way analysis of variance (ANOVA) as indicated in the figure legends. Statistical
analyses were performed in GraphPad Prism 5.03 for Windows (GraphPad
Software, San Diego, CA). Two-tailed p values < 0.05 were considered statistically
significant.
Results
Clinical signs of influenza infection
All influenza-inoculated mice showed clinical signs of infection, including weight loss,
lethargy, and pyrexia. Four influenza-infected mice were prematurely taken out of the
experiment because of signs of severe infection. Body weight decreased in all
influenza-infected mice in the acute phase of infection, whereas it remained stable in
mock-inoculated mice (Fig. 1). From day 7 onwards, body weight started to increase,
marking the recovery phase of influenza infection (Fig. 1).
Cytokines in plasma and lung homogenates
Influenza infection by itself did not result in increased plasma levels of any of the cyto-
kines measured at both 4 and 10 days post-infection (Fig. 2). Expectedly, LPS
Fig. 1 Body weight of influenza- or mock-inoculated mice. Data are presented as mean with SEM. Dagger
indicates the two time points at which mice in the respective groups were sacrificed
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administration led to profoundly increased plasma concentrations of TNF-α, IL-6, and
IL-10. Although TNF-α and IL-6 plasma levels appeared to be somewhat higher in mice
challenged with LPS 4 days after influenza infection compared with mock-inoculated
mice, this did not reach statistical significance (p = 0.12 and p = 0.86, respectively).
Plasma concentrations of the anti-inflammatory cytokine IL-10 were however signifi-
cantly enhanced in mice challenged with LPS 4 days after influenza infection. No differ-
ences in any of the plasma cytokine levels were measured between influenza-infected
and mock-inoculated mice at 10 days.
In lung homogenates, influenza by itself caused mildly elevated levels of TNF-α,
IL-1β, IL-6, and IL-10 at 4 days post-infection and to a lesser extent at 10 days after in-
fection (Fig. 3). Similar to what was found in plasma, LPS challenge also led to in-
creased concentrations of all measured cytokines in lung tissue. A synergistic increase
of all pro-inflammatory cytokines in the lungs was found in influenza-infected mice
challenged with LPS 4 days later and, to a lesser extent, in mice challenged with LPS
10 days post-influenza infection. For IL-10, the potentiating effect was additive rather
Fig. 2 Plasma levels of TNF-α, IL-6, and IL-10 in mice that received influenza/mock followed by LPS/NaCl 4
or 10 days later. Data are presented as scatter-dot plots with horizontal lines indicating the mean value.
*p < 0.05, **p < 0.01, ***p < 0.001 (calculated by unpaired Student’s t tests)
Fig. 3 Levels of TNF-α, IL-1β, IL-6, and IL-10 in lung homogenates of mice that received influenza/mock
followed by LPS/NaCl 4 or 10 days later. Data are presented as scatter-dot plots with horizontal lines
indicating the mean value. *p < 0.05, **p < 0.01, ***p < 0.001, #p = 0.05–0.10 (calculated by unpaired
Student’s t tests)
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than synergistic, only observed at 4 days post-influenza infection, and reached a trend
towards statistical significance.
Pulmonary MPO content
In accordance with pulmonary cytokine levels, influenza infection by itself led to in-
creased MPO content in the lungs 4 days after infection and tended to result in increased
MPO content 10 days post-infection (Fig. 4). Again, LPS administration also resulted in
increased MPO levels in lung tissue, and there was a trend towards enhanced MPO con-
tent in influenza-infected mice challenged with LPS 4 days after infection.
Discussion
In the present study, we demonstrate that a systemic LPS challenge in the acute phase
of influenza infection (4 days post-infection) results in an enhanced pulmonary, but not
systemic pro-inflammatory cytokine response. This effect was synergistic rather than
additive, indicating that influenza infection actually modulates the immune response to
a subsequent challenge with LPS. Furthermore, this effect remained present, although
less pronounced, in the recovery phase of influenza infection (10 days post-infection).
The LPS-induced increase in MPO content in lung homogenates, reflecting pulmonary
neutrophil influx or sequestration, tended to be enhanced in the acute phase of influ-
enza infection as well. These results suggest that influenza infection, especially in the
acute phase, may cause a more pronounced pulmonary pro-inflammatory immune re-
sponse upon a secondary bacterial infection.
Our results are in accordance with in vitro data reporting a cellular priming effect of influ-
enza observed upon secondary stimulation with LPS [4–8], as well as with other murine in
vivo studies that report increased inflammation and pulmonary neutrophil influx or seques-
tration upon a secondary bacterial infection or LPS challenge in the acute phase of influenza
infection [9, 10]. For example, a preceding influenza infection in mice gravely enhanced
lung injury induced by a secondary infection with Streptococcus pneumoniae 7 days later,
resulting in a severe necrotic pneumonia accompanied by increased mortality [10]. Also,
Fig. 4 MPO content in lung homogenates of mice that received mock/influenza followed by NaCl/LPS 4 or
10 days later. Data are presented as scatter-dot plots with horizontal lines indicating the mean value.
*p < 0.05, **p < 0.01, ***p < 0.001, #p = 0.05–0.10 (calculated by unpaired Student’s t tests)
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the increased MPO content observed in our study is an important hallmark of acute re-
spiratory distress syndrome (ARDS) [15, 16], a severe complication of influenza infection
caused by excessive pulmonary inflammation. These and our study reveal that the enhan-
cing effect on the pro-inflammatory innate immune response is most evident in the lungs,
probably because the influenza-induced damage and consequent inflammatory effects are
most pronounced at this site. In this context, our data are in line with the recommendation
to use corticosteroids in patients with severe influenza infections in the Intensive Care
Unit to counteract the pulmonary hyperinflammatory response causing ARDS. Several
underlying mechanisms may contribute to the observed effects. At the cellular level, stud-
ies have shown that influenza and certain bacterial pathogens, such as Haemophilus influ-
enzae and Streptococcus pneumoniae, utilize similar immunological pathways and that the
overlap in the inflammatory mediators produced thereby creates augmentation of the im-
mune response during sequential infection, in turn causing immunopathology [17, 18].
Furthermore, it has been hypothesized that influenza stimulates TNF-α gene transcription
activators or may interfere with labile transcription repressor proteins and stabilizes
TNF-α mRNA by delaying its degradation [8]. Alternatively, the increased lung MPO
levels observed do not necessarily reflect PMN infiltration into the lungs, but may (also)
result from PMNs trapped in the vasculature, as circulating activated neutrophils become
rigid and can be trapped within the small capillaries of the lung [19]. As such, increased
entrapment of leukocytes in the pulmonary vasculature during influenza infection could
also contribute to the enhanced inflammatory cytokine levels upon LPS challenge. We
can only speculate on this, because no histological data are available, which represents a
limitation of this work.
It may be argued that the enhanced pro-inflammatory immune response induced by
influenza serves as a means to efficiently eliminate the primary pathogen and to en-
hance host defense towards a secondary infection. For instance, pro-inflammatory cyto-
kines are induced in influenza-infected cells to limit viral replication and to initiate
downstream immune responses [20]. However, this is not supported by previous work,
where an increased bacterial burden was observed irrespective of an enhanced or sup-
pressed response [11–13]. Several explanations for this observation may be put for-
ward. First, next to potentiating pro-inflammatory cytokine responses, the present
study and work by others [11] have shown that influenza infection also potentiates pro-
duction of the key anti-inflammatory cytokine IL-10, which was demonstrated to be
crucial in facilitating bacterial outgrowth upon secondary challenge with Streptococcus
pneumoniae [11]. Second, influenza may on the one hand prime for production of in-
nate cytokines produced by myeloid cells, but impair T cell-derived cytokines that are
instrumental for the adaptive immune response. This was elegantly demonstrated by
Kudva et al., who showed that, in line with our results, infection with Staphylococcus
aureus 6 days after influenza resulted in increased pulmonary levels of innate cytokines
such as IL-6 and MCP-1, and increased neutrophil influx to the lungs, but decreased
concentrations of T-cell-derived IL-17 and IL-22, which were demonstrated to play a
pivotal role in fending off the staphylococcal infection [21].
Whereas the enhancing effects of influenza on pro-inflammatory innate immune pa-
rameters were less pronounced at 10 days post-infection, a suppressed response was
neither evident. This could be partly biased by the exclusion of two mice in both
recovery groups due to severe influenza infection. However, it might also be argued
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that 10 days post-infection is too soon for these effects to manifest. For example, pro-
found desensitization towards LPS and flagellin, another Toll-like receptor (TLR) ligand,
was observed in alveolar macrophages obtained from mice up to 6 weeks after influenza
infection [22]. Furthermore, the direction of the response upon a secondary challenge is
probably highly dependent on the pathogen or stimulus used, each using distinct intracel-
lular signaling pathways. With regard to this, it is well-known that influenza virus particu-
larly predisposes to Aspergillus fumigatus, which is present in 25% of all influenza patients
[23, 24], causing infections such as invasive pulmonary aspergillosis that are associated
with very high mortality rates. As different mechanisms may be important in host defense
towards various pathogens, the specific response towards Aspergillus fumigatus could be sup-
pressed by a preceding influenza infection. The use of corticosteroids may be another im-
portant factor in the observed vulnerability towards particular secondary infections, as
steroid use was shown to be independently associated with the presence of Aspergillus fumi-
gatus in sputum of cystic fibrosis patients [25] and with a substantially increased risk of
community-acquired Staphylococcus aureus bacteremia [26]. Furthermore, a meta-analysis
revealed that the use of corticosteroids was significantly associated with nosocomial infec-
tions [27]. To the best of our knowledge, these putative detrimental effects of corticosteroid
treatment during influenza on secondary infections have yet to be studied systematically
in animal models. In any case, it remains to be determined whether the overall effects of
corticosteroid treatment are beneficial or not, as they may lead to increased susceptibility
in a subset of influenza virus-infected patients but may also provide health benefits in an-
other subset of influenza virus-infected patients.
Conclusions
An LPS challenge in the acute phase of influenza infection results in an enhanced
pulmonary pro-inflammatory innate immune response. These data increases our
insight concerning viral-bacterial interplay. Combined with previous findings, it ap-
pears that this enhanced pro-inflammatory response does not lead to protection
against secondary infections but rather causes immunopathology leading to dam-
age, and thereby to organ failure.
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